Abstract
The purpose of this study was to provide guidance to patients with type 2 diabetes mellitus when their insulin device was changed since insulin therapy may be hampered when a device change is made.Informed consent was obtained from the 18 patients who took part in it.They had been using NovoRapid® 30 Mix FlexPen® (30 MixF).After replacing it with Humalog® Mix 25 MirioPen® (Mix 25 M),we checked usability for the new device.
After replacement,there was no significant change in HbA1C or quality of life (QOL) and patients expressed their positive feelings regarding the replacement device as follows:“It is easy to hold”,“I only have to press lightly to inject”and“There is no sound when injecting”.Negative impressions were expressed as follows:“I cannot tell when the end of injection is”,“The cap does not open”,and“It is difficult to sterilize”.
In conclusion,we obtained good feedback on how patients felt about changing to the MirioPen® .In the future,we will make efforts to provide proper guidance to patients on the basis of the opinions we obtained from the patients in this study.
